FDA announced several required updates to opioid prescribing information in April 2023. The changes apply to both immediate release (IR) and extended release/long-acting (ER/LA) opioid pain medications.

Sonya Collins

According to a randomized clinical trial published April 2023 in JAMA Otolaryngology–Head & Neck Surgery, self-fitted OTC hearing aids demonstrated similar clinical outcomes to audiologist-fitted hearing aids using best practices in patients with mild-to-moderate hearing loss within a 6-week period.

Clarissa Chan, PharmD

While COVID-19 continues to evolve, recommendations for vaccinating against it are changing as well.

Olivia C. Welter, PharmD

Updates from FDA

In March of this year, FDA approved the first and only calcitonin gene–related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.

Lauren Howell, PharmD